ATE455539T1 - Darreichungsformen mit verlängerter wirkstofffreisetzung - Google Patents

Darreichungsformen mit verlängerter wirkstofffreisetzung

Info

Publication number
ATE455539T1
ATE455539T1 AT02754105T AT02754105T ATE455539T1 AT E455539 T1 ATE455539 T1 AT E455539T1 AT 02754105 T AT02754105 T AT 02754105T AT 02754105 T AT02754105 T AT 02754105T AT E455539 T1 ATE455539 T1 AT E455539T1
Authority
AT
Austria
Prior art keywords
oral administration
daily oral
dosage forms
extended release
twice
Prior art date
Application number
AT02754105T
Other languages
English (en)
Inventor
Peter Truog
Original Assignee
Lunamed Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lunamed Ag filed Critical Lunamed Ag
Application granted granted Critical
Publication of ATE455539T1 publication Critical patent/ATE455539T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
AT02754105T 2001-09-10 2002-09-04 Darreichungsformen mit verlängerter wirkstofffreisetzung ATE455539T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01810865A EP1291015A1 (de) 2001-09-10 2001-09-10 Darreichungsformen mit verlängerter Wirkstofffreisetzung
PCT/CH2002/000486 WO2003022253A1 (de) 2001-09-10 2002-09-04 Dosage forms having prolonged active ingredient release

Publications (1)

Publication Number Publication Date
ATE455539T1 true ATE455539T1 (de) 2010-02-15

Family

ID=8184126

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02754105T ATE455539T1 (de) 2001-09-10 2002-09-04 Darreichungsformen mit verlängerter wirkstofffreisetzung

Country Status (12)

Country Link
US (1) US7611729B2 (de)
EP (2) EP1291015A1 (de)
JP (1) JP2005508901A (de)
CN (1) CN100508965C (de)
AT (1) ATE455539T1 (de)
AU (1) AU2002322964B2 (de)
CA (1) CA2459165C (de)
DE (1) DE60235178D1 (de)
DK (1) DK1427396T3 (de)
ES (1) ES2339536T3 (de)
PT (1) PT1427396E (de)
WO (1) WO2003022253A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1291015A1 (de) 2001-09-10 2003-03-12 Lunamed AG Darreichungsformen mit verlängerter Wirkstofffreisetzung
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
JP2006520796A (ja) 2003-03-17 2006-09-14 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼインヒビター
WO2006066133A2 (en) 2004-12-16 2006-06-22 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7642253B2 (en) 2005-05-11 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20070004805A1 (en) * 2005-07-01 2007-01-04 Navinta Llc Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate
KR20080032188A (ko) 2005-07-14 2008-04-14 다케다 샌디에고, 인코포레이티드 히스톤 탈아세틸화 효소 억제제
US20070202164A1 (en) * 2006-02-28 2007-08-30 Hutchison Medipharma Enterprises Limited Andrographis Extract Formulations
FR2959129B1 (fr) * 2010-04-21 2013-02-01 Lucane Pharma Particules comprenant du 4-phenylbutyrate de sodium, procede de preparation et utilisations
EP2389932A1 (de) * 2010-05-28 2011-11-30 Lunamed AG Zusammensetzungen zur Verwendung bei Erbkrankheiten, die 4-Phenylbuttersäure und deren Salze umfassen
EP2397458A1 (de) 2010-06-21 2011-12-21 Lunamed AG Organische Salze und Co-Kristalle von Phenylbuttersäure
EP2599481A1 (de) * 2011-11-30 2013-06-05 Lunamed AG 4-Phenylbuttersäure zur Behandlung oder Vorbeugung von verschiedenen Erkrankungen
EP2599767A1 (de) 2011-11-30 2013-06-05 Lunamed AG Phenylbutyl-Derivate
EP2599483A1 (de) 2011-11-30 2013-06-05 Lunamed AG 4-Phenylbuttersäure-Formulierung
EP2599482A1 (de) * 2011-11-30 2013-06-05 Lunamed AG Therapeutische Verwendung von niedrig dosiertem Glyceryl Tri-(4-Phenylbutyrat)
EP2599477A1 (de) 2011-11-30 2013-06-05 Lunamed AG Verzögerte Freisetzungsformulierung mit 4-Phenylbuttersäure
EP2607367A1 (de) 2011-12-21 2013-06-26 Lunamed AG Glycerol-Phenyl-Butyrat-Derivate
EP2607366A1 (de) 2011-12-21 2013-06-26 Lunamed AG Glycerol-Phenyl-Butyrat-Ester
EP2698155A1 (de) * 2012-08-16 2014-02-19 Lunamed AG Pharmazeutische Dosierungseinheit enthaltend 4-Phenylbuttersäure
EP2698156A1 (de) 2012-08-16 2014-02-19 Lunamed AG Phenylbutyrensäure zur Chemoprävention
RU2635539C2 (ru) * 2016-03-10 2017-11-13 Федеральное государственное бюджетное учреждение науки Институт высокомолекулярных соединений Российской академии наук Полимерные водорастворимые производные 4-фенил-бутановой кислоты, обладающие противоопухолевой активностью
MX391305B (es) 2016-03-15 2025-03-21 Acer Therapeutics Inc Composiciones degustables que incluyen fenilbutirato de sodio y usos de las mismas.
CN106109429A (zh) * 2016-07-26 2016-11-16 北京百奥药业有限责任公司 一种苯丁酸钠片剂及其制备方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4457942A (en) 1982-08-20 1984-07-03 Brusilow Saul W Process for waste nitrogen removal
US5605930A (en) 1991-10-21 1997-02-25 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for treating and preventing pathologies including cancer
US6037376A (en) * 1991-10-21 2000-03-14 The United States Of America As Represented By The Department Of Health And Human Services Methods for therapy of cancer
EP0567613B1 (de) * 1991-10-21 2002-02-20 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Zusammensetzungen zur behandlung und vorbeugung von krebs
US5635532A (en) * 1991-10-21 1997-06-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia
WO1995010281A1 (en) 1993-10-13 1995-04-20 Merck & Co., Inc. Combination therapy for hiv infection
US5569680A (en) * 1995-02-13 1996-10-29 Trustees Of The Univ. Of Penna Method of treating inflammatory bowel disease with tributyrin
US6011000A (en) 1995-03-03 2000-01-04 Perrine; Susan P. Compositions for the treatment of blood disorders
US5912269A (en) * 1996-04-30 1999-06-15 Vertex Pharmaceuticals, Inc. Butyrate prodrugs derived from lactic acid
US5763488A (en) * 1995-10-30 1998-06-09 Vertex Pharmaceuticals Incorporated Methods and compositions using butyrate esters of threitol
US6635632B1 (en) * 1996-12-23 2003-10-21 Athena Neurosciences, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US5939455A (en) 1997-03-11 1999-08-17 Beacon Laboratories, Inc. Therapeutic augmentation of oxyalkylene diesters and butyric acid derivatives
US6207195B1 (en) * 1997-06-13 2001-03-27 The Johns Hopkins University Therapeutic nanospheres
US5972995A (en) * 1997-10-16 1999-10-26 Children's Hospital Medical Center Of Northern California Compositions and methods for cystic fibrosis therapy
WO1999026657A1 (en) 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
US6262116B1 (en) 1998-01-23 2001-07-17 Sloan-Kettering Institute For Cancer Research Transcription therapy for cancers
CA2344717A1 (en) * 1998-09-28 2000-04-06 The Johns Hopkins University Adrenoleukodystrophy treatments and drug screening
CA2366650A1 (en) * 1999-03-19 2000-09-28 Michael Su Oral low dose butyrate compositions
US6403646B1 (en) 1999-06-30 2002-06-11 David H. Perlmutter Method for the treatment of alpha-1-antitrypsin deficiency and related pathologies
AU4517201A (en) * 1999-12-08 2001-06-18 Vanderbilt University Modulation of in vivo glutamine and glycine levels in the treatment of autism
US6656912B2 (en) * 2000-01-20 2003-12-02 Washington University In St. Louis Methods to treat α1-antitrypsin deficiency
FR2810547B1 (fr) 2000-06-22 2004-01-30 Pasteur Institut Utilisation d'acides en c2-c10 pour la prevention des infections a bacteries a gram negatif
US6987131B1 (en) 2000-06-26 2006-01-17 Burzynski Stanislaw R Phenylacetic acid compositions for treating or preventing hypercholesterolemia
WO2002028348A2 (en) * 2000-10-04 2002-04-11 The Children's Hospital Of Philadelphia Compositions and methods for treatment of cystic fibrosis
WO2002055017A2 (en) * 2000-11-21 2002-07-18 Wake Forest University Method of treating autoimmune diseases
US20030166554A1 (en) * 2001-01-16 2003-09-04 Genset, S.A. Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
BR0206495A (pt) 2001-01-16 2006-01-24 Genset Sa Tratamento de distúrbios de cns empregando antagonistas de oxidase de d-aminoácido e oxidase de d-aspartato
AU2002226650A1 (en) 2001-01-18 2002-07-30 Arnold Hoffman Redox therapy for tumors
ATE329578T1 (de) 2001-02-14 2006-07-15 Forte Iq B V Pharmazeutische zusammensetzung enthaltend xanthangummi
CA2442366C (en) 2001-03-27 2012-09-25 Circagen Pharmaceutical, Llc Histone deacetylase inhibitors
US7312247B2 (en) * 2001-03-27 2007-12-25 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US6495719B2 (en) * 2001-03-27 2002-12-17 Circagen Pharmaceutical Histone deacetylase inhibitors
US8026280B2 (en) * 2001-03-27 2011-09-27 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
DE60113645T2 (de) 2001-04-10 2006-07-06 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Verwendung von Histonedeacetylasehemmern zur Behandlung von Papillomaviren assoziierte Krankheiten
WO2002090534A1 (en) 2001-05-02 2002-11-14 The Regents Of The University Of California Method for treating neurodegenerative, psychiatric and other disorders with deacetylase inhibitors
US20040142859A1 (en) * 2002-05-02 2004-07-22 Steffan Joan S. Method for treating neurodegenerative, psychiatric, and other disorders with deacetylase inhibitors
US6372938B1 (en) * 2001-05-21 2002-04-16 Stanislaw R. Burzynski Synthesis of 4-phenylbutyric acid
EP1291015A1 (de) 2001-09-10 2003-03-12 Lunamed AG Darreichungsformen mit verlängerter Wirkstofffreisetzung
US6958352B2 (en) * 2002-02-08 2005-10-25 Smithkline Beecham Corporation Compounds for inhibiting insulin secretion and methods related thereto
US20040077591A1 (en) * 2002-03-28 2004-04-22 The Brigham And Women's Hospital, Inc. Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and Alzheimer's Disease

Also Published As

Publication number Publication date
AU2002322964B2 (en) 2008-10-16
DE60235178D1 (de) 2010-03-11
HK1071847A1 (zh) 2005-08-05
PT1427396E (pt) 2010-04-14
US7611729B2 (en) 2009-11-03
CN100508965C (zh) 2009-07-08
WO2003022253A1 (de) 2003-03-20
EP1427396B1 (de) 2010-01-20
CN1553799A (zh) 2004-12-08
CA2459165C (en) 2011-07-19
US20040180962A1 (en) 2004-09-16
EP1427396A1 (de) 2004-06-16
CA2459165A1 (en) 2003-03-20
ES2339536T3 (es) 2010-05-21
JP2005508901A (ja) 2005-04-07
EP1291015A1 (de) 2003-03-12
DK1427396T3 (da) 2010-05-25

Similar Documents

Publication Publication Date Title
ATE455539T1 (de) Darreichungsformen mit verlängerter wirkstofffreisetzung
JP2006501240A5 (de)
ES2180646T3 (es) Formulaciones liquidas orales de alendronato.
NO20045656L (no) Oftalmologisk anvendelse av roflumilast for behandlingen av oyesykdommer
CA2326517A1 (en) New galenic preparations of meloxicam for oral administration
PT1326613E (pt) Utilizacao de derivados de imidazo[1,2-a]piridin-,imidazo[1,2-a]pirimidin- e imidazo[1,2-a]pirazin-3-il-amina substituidos para a fabricacao de medicamentos para inibicao de nos
DK0503440T3 (da) Sumatriptanholdige lægemidler
EA200300046A1 (ru) Быстро увеличивающаяся в объеме композиция для удерживания и контролированного выделения терапевтических агентов в желудке и лекарственные формы, включающие композицию
RU98111594A (ru) Фармацевтические композиции, включающие флурбипрофен
DK1333880T3 (da) Indretninger med coatede mikrofremspring til medikamentafgivelse gennem huden
CA2503810A1 (en) Therapeutic agent for fibromyalgia
WO2006056711A3 (fr) Medicament oral a liberation modifiee d'au moins un principe actif sous forme multimicrocapsulaire
JP2002526407A5 (de)
ATE298324T1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
RU2002121546A (ru) Вещества, предназначенные для лечения псориаза
JP2003514025A5 (de)
JP2002540148A5 (de)
JP2002537246A5 (de)
CA2474703A1 (en) Therapeutic agent of glaucoma comprising bunazosin and prostaglandins
MXPA02009603A (es) Terapias de dosis divididas con actividad de deterioro vascular.
JP2002501021A5 (de)
CA2515259A1 (en) Use of acetylsalicylic acid for the treatment of hemorrhoidal disease
AU2001258859A1 (en) Pralmorelin-containing nasal drop preparations
DE60012575D1 (de) Nsaid enthaltendes wasserfreies gel zur topischen anwendung in der mundhöhle
RU2005131943A (ru) Лечебные и/или профилактические средства для хронических болезней кожи

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1427396

Country of ref document: EP